Zurich launches Precision CancerCare™ and Second Medical Opinion services for Group Risk customers

This service is provided in partnership with Further, a leading specialist in the design and development of niche health service solutions.

As Cancer is the leading cause of claim for Zurich Corporate Risk, making sure customers, and their employees, have access to the very best support is a primary focus.

Precision CancerCare™

Every tumour and every cancer patient are different, and treatment plans should reflect this. Precision CancerCare™ provides access to comprehensive genetic testing which uses the latest tumour profiling technology and expert medical panels. The service is accessible for all advanced and complex cancers2 where the biggest impact is expected.

By understanding the ‘genetic make-up’ of the cancer, the Further service provides a customised treatment plan specific to the molecular drivers of the tumour, which can potentially improve a patient’s outcomes, reduce negative side effects of unnecessary treatments and help improve overall quality of life. The service also delivers an expert clinical report which provides personalised guidance regarding cancer treatment options and advice.

Key features:

• Comprehensive genetic testing in world leading laboratories, reviewed by precision medicine experts - understanding the genetic make-up of the cancer means a more precise diagnosis.
• An Expert Clinical Report with personalised treatment options.
• If a hereditary mutation is identified, that could affect children, they are offered testing and counselling to help them make decisions about future health.
• Navigation assistance on clinical trials.
• Co-ordination and collaboration with the employee’s treating clinician.

Second Medical Opinion

Customers will also have access to a new Second Medical Opinion (SMO) service, also provided by Further, helping to offer peace of mind about a diagnosis or treatment plans.

The SMO service offers access to an independent evaluation of a diagnosis, treatment plan, or medical condition from a qualified medical professional other than an individual’s primary doctor. This can help to empower them with knowledge and offer support to help them better understand their medical condition, to be able to actively participate in their health decisions.

The service is available once per unique diagnosis, and support is offered for spouses or partners, and dependent children up to age 22.

Key features:

• Independent, in-depth review of a diagnosis and treatment by medical experts in all specialties for eligible conditions covered by the service such as cancer, heart surgery, neurosurgery, bone marrow transplant and live-donor organ transplant.
• Access to a pool of global experts.
• A full clinical report of results and recommendations, providing information and options for next steps.
• A dedicated Case Navigator to address any questions to help inform health decisions.
• Access to Precision CancerCare™ via the Second Medical Opinion+ service.

Commenting on the launch, Cindy Warden, Head of Zurich Corporate Risk said:

“Zurich is delighted to partner with Further Group to significantly enhance the value-added services available to our Group Risk customers. Precision CancerCare™ is a leading edge clinical capability and has huge potential to improve outcomes for individuals with a serious cancer diagnosis.”

Frank Ahedo, Chief Executive Officer at Further said:

“We are thrilled to strengthen our partnership with Zurich Insurance in the UK. We have truly found a partner that shares our passion for innovation and our ambition to make a meaningful impact by supporting those facing critical healthcare challenges.”

¹New policies or existing customers going through a rate retest, initially quoted from 1 April 2025, have access to Precision CancerCare™ and Second Medical Opinion+ service provided by Further.
²In order to be eligible to access the Precision CancerCare service, a patient’s cancer must be either not responding to the first line of treatment, diagnosed as stage 3 or 4, from an unknown primary source or be a rare form of cancer (Cancers with an incidence of <6/100.000 included on the Surveillance of Rare Cancers in Europe RARECARE list published on the RARECARENet website)